Found 1 Presentation For Request "406p"

Colorectal cancer

406P - Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan

Presentation Number
  • Chou-Chen Chen (Taichung City, Taiwan)
Sun, 11.09.2022



Cetuximab plus chemotherapy has been approved as first-line (1L) treatment for mCRC. However, real-world evidence of cetuximab for mCRC in Asian population remains inadequate. The objective of this large-scale, multicenter retrospective study was to report real-world treatment patterns and clinical outcomes of Taiwanese patients with RAS WT mCRC received 1L cetuximab-based chemotherapy.


From November 2016 to August 2020, data of mCRC patients with RAS WT who received 1L cetuximab-based chemotherapy from 13 hospitals in Taiwan were analyzed. Patient characteristics, treatment and survival outcomes were examined.


A total of 698 mCRC patients (67.6% male) received the 1L cetuximab-based chemotherapy, with a median age of 61.8 years. 626 had a left-sided primary tumor. 423 had liver metastases. 138 of patients received metastasectomy during or after 1L cetuximab treatment. In the overall patient population, the ORR and DCR were 62.2% and 88.2%, respectively. With a median follow-up of 22.5 months, the median OS, PFS and DOT were 34.6, 14.7 and 9.6 months, respectively. Further stratified analysis by tumor location demonstrated that left-sided mCRC patients had significantly longer OS than right-sided in RAS WT population (36.3 vs. 19.9 months, p<0.001). On the other hands, left-sided and right-sided mCRC showed comparable ORR (62.8% vs. 54.8%), CR rate (9.4% vs. 12.9%) and metastasectomy rate (20.3% vs. 16.2%). In addition, patients who underwent metastasectomy had significantly improved OS than those without resection (53.2 vs. 29.0 months, p<0.001). Left-sided mCRC patients without metastasectomy also showed to have significantly better OS (29.8 vs 16.7; p<0.001) than right-sided. However, comparable survival outcome was observed between left-sided and right-sided mCRC received metastasectomy (54.3 vs. 52.3 months).


1L cetuximab therapy shows promising efficacy and safety in Taiwanese mCRC patients in real-world setting. Patients underwent metastasectomy after or during 1L cetuximab therapy demonstrated to have an improved OS in both left-sided and right-sided mCRC.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.